- Home
- NERV
as 10-28-2025 4:00pm EST
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 14.6M | IPO Year: | 2014 |
| Target Price: | $5.00 | AVG Volume (30 days): | 9.3M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.15 - $12.46 | Next Earning Date: | 11-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Minerva Neurosciences Inc News
NERV Breaking Stock News: Dive into NERV Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Top Midday Gainers
Associated Press Finance
8 days ago
BC-Most Active Stocks
GlobeNewswire
8 days ago
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Leasing Life
5 months ago
Ares and Ansley Park Capital provide asset-based and equipment financing to Shimmick
Offshore Technology
5 months ago
BP, EOG achieve first gas from Mento field, offshore Trinidad
AFP
5 months ago
Macron urges Asia, Europe to unite to resist 'spheres of coercion'
Footwear News
5 months ago
Name Game: Shoe Carnival Is Converting More Stores to Shoe Station Banner
Business Wire
5 months ago
Form 8.3 - American Axle & Manufacturing Holdings, Inc.
Compare NERV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NERV Minerva Neurosciences Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.